In this issue:
Mirikizumab for psoriasis
Predictors of time to relapse following ustekinumab withdrawal
Secukinumab in psoriasis patients with a history of malignancy
Deucravacitinib vs placebo and apremilast for plaque psoriasis
Deucravacitinib for plaque psoriasis
Genetic variations in IL-17A associated with psoriasis risk
Drug survival of IL-17 and IL-23 inhibitors
Dermatological nurse support improves outcomes with topical drugs
Reactivation of latent tuberculosis with biologic therapies
Comorbidities in Chilean patients with psoriasis
Please login below to download this issue (PDF)